Current
17.6×
5-Year Average
81.6×
All-Time High
1114.6×
All-Time Low
6.8×
P/E Ratio daily chart for Gilead Sciences (GILD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/E Ratio for Gilead Sciences (GILD) from 2001 to 2025
| 2025 | $152.44B | $8.51B | 17.9× | -222.2× | |
| 2024 | $115.28B | $480.00M | 240.2× | +222.3× | |
| 2023 | $101.10B | $5.66B | 17.8× | -5.6× | |
| 2022 | $107.48B | $4.59B | 23.4× | +8.8× | |
| 2021 | $91.20B | $6.22B | 14.7× | -579.8× | |
| 2020 | $73.12B | $123.00M | 594.4× | +579.2× | |
| 2019 | $82.26B | $5.39B | 15.3× | +0.5× | |
| 2018 | $80.69B | $5.46B | 14.8× | -5.4× | |
| 2017 | $93.63B | $4.63B | 20.2× | +13.3× | |
| 2016 | $94.24B | $13.50B | 7.0× | -1.0× | |
| 2015 | $145.31B | $18.11B | 8.0× | -3.7× | |
| 2014 | $141.96B | $12.10B | 11.7× | -25.7× | |
| 2013 | $115.19B | $3.07B | 37.5× | +16.0× | |
| 2012 | $55.73B | $2.59B | 21.5× | +10.7× | |
| 2011 | $30.19B | $2.80B | 10.8× | +0.7× | |
| 2010 | $29.30B | $2.90B | 10.1× | -4.7× | |
| 2009 | $38.94B | $2.64B | 14.8× | -8.6× | |
| 2008 | $46.59B | $2.00B | 23.4× | -3.0× | |
| 2007 | $42.64B | $1.62B | 26.4× | — | |
| 2006 | $29.70B | −$1.19B | — | — | |
| 2005 | $23.97B | $813.91M | 29.5× | -4.1× | |
| 2004 | $15.09B | $449.37M | 33.6× | — | |
| 2003 | $11.76B | −$72.00M | — | — | |
| 2002 | $6.67B | $72.10M | 92.5× | -27.4× | |
| 2001 | $6.27B | $52.27M | 119.9× | — |
- 202517.9×
- 2024240.2×
- 202317.8×
- 202223.4×
- 202114.7×
- 2020594.4×
- 201915.3×
- 201814.8×
- 201720.2×
- 20167.0×
- 20158.0×
- 201411.7×
- 201337.5×
- 201221.5×
- 201110.8×
- 201010.1×
- 200914.8×
- 200823.4×
- 200726.4×
- 2006—
- 200529.5×
- 200433.6×
- 2003—
- 200292.5×
- 2001119.9×
About P/E Ratio at Gilead Sciences (GILD)
Gilead Sciences (GILD) P/E ratio is 17.6× as of June 5, 2026. The 5-year average is 81.6×. The sector median currently stands at 25.0×. The current ratio is at the 33th percentile of its own 10-year history.
Gilead Sciences (GILD) historical P/E ratio has ranged from a low of 6.8× (2016) to a high of 1114.6× (2025) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Gilead Sciences P/E Ratio by Year
Gilead Sciences P/E Ratio 2025: 17.9×
Gilead Sciences (GILD) P/E ratio in 2025 was 17.9×, contracted from 240.2× the prior year.
Gilead Sciences P/E Ratio 2024: 240.2×
Gilead Sciences (GILD) P/E ratio in 2024 was 240.2×, expanded from 17.8× the prior year.
Gilead Sciences P/E Ratio 2023: 17.8×
Gilead Sciences (GILD) P/E ratio in 2023 was 17.8×, contracted from 23.4× the prior year.
Gilead Sciences P/E Ratio 2022: 23.4×
Gilead Sciences (GILD) P/E ratio in 2022 was 23.4×, expanded from 14.7× the prior year.
Gilead Sciences P/E Ratio 2021: 14.7×
Gilead Sciences (GILD) P/E ratio in 2021 was 14.7×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Gilead Sciences (GILD), ranked by P/E ratio.
| 23.1× | |
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric